Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Mar 31, 2024
Revenue declined in the current quarter compared to both the prior quarter and the same quarter last year. The decrease from the preceding quarter was more pronounced than the slight decline from a year earlier.
Key takeaway
Quarter ended Mar 31, 2024 · FY2024 Q1
Revenue declined in the current quarter compared to both the prior quarter and the same quarter last year. The decrease from the preceding quarter was more pronounced than the slight decline from a year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.1B
Revenue reported for this quarter.
Quarter-over-quarter
-8.4%
Change from the immediately preceding quarter.
Year-over-year
-0.5%
Change from the comparable year-ago quarter.
Trailing four quarters
$13.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2023 | $3.2B | +10.5% |
| Sep 30, 2023 | $3.4B | +14.5% |
| Dec 31, 2023 | $3.4B | +0.6% |
| Mar 31, 2024 | $3.1B | -0.5% |
Revenue performance
The reported revenue moved lower, reversing the growth seen in the prior three quarters. The sequential decline was the first in the trailing twelve-month period.
Quarterly comparison
Compared with the immediately preceding quarter, revenue fell by a mid-single-digit percentage. Versus the same quarter one year earlier, revenue was nearly flat, with a minimal decline.
What to watch
The filing context does not provide a specific explanation for the revenue decline, so the cause remains unaddressed in the report.